uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Stock Information for Aligos Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aligos Therapeutics Inc.

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
uniQure to Announce First Quarter 2025 Financial Results
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.